Most ophthalmologists are familiar and comfortable with the application of devices and drugs in their daily practice.
Devices such as a new IOL implant are approved by the FDA Center for Devices and Radiological Health, and we have a steady flow of new devices into the ophthalmology marketplace. Drugs, which represent the application of one or more molecules to prevent or treat disease, are regulated by the FDA Center for Drug Evaluation and Research, and again, we have new molecules approved to treat our patients every year.
Now we are (Read more...)